Summary (tl;dr)

A new, highly mutated COVID-19 variant, officially designated BA.3.2 and informally dubbed "Cicada," is gaining global attention due to its significant genetic differences from previous strains and its potential to evade existing immunity. While not yet dominant in the U.S., it has seen increasing prevalence in parts of Europe, prompting public health officials to monitor its spread closely.

Essential Background

The SARS-CoV-2 virus, responsible for COVID-19, continuously evolves through mutations, leading to the emergence of new variants over time. These mutations can influence transmissibility, immune escape, and symptom profiles. Current COVID-19 vaccines are primarily designed to target older strains, and new variants can sometimes reduce the effectiveness of immunity gained from prior infections or vaccinations. The BA.3.2 variant was initially identified in South Africa in November 2024.

The Full Story

The BA.3.2 variant has earned the nickname "Cicada" because, much like the insect, it appeared in 2024, went dormant, and then resurfaced more noticeably in late 2025 and early 2026, suggesting it may have evolved quietly "underground." This variant is characterized by a substantial number of mutations—approximately 70 to 75 in its spike protein—making it genetically distinct from dominant strains like JN.1 and XFG.

Public health experts, including the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), are closely monitoring the "Cicada" variant. The WHO classified BA.3.2 as a "variant under monitoring" in December 2025. It was first detected in a U.S. traveler in June 2025 and has since been identified in wastewater samples across at least 25 U.S. states and Puerto Rico, as well as in clinical and traveler samples. While its prevalence in the U.S. remains low (around 0.19% of sequenced cases as of February 11, 2026), BA.3.2 has gained traction in Europe, accounting for about 30% of cases in countries like Germany, Denmark, and the Netherlands between November 2025 and January 2026.

Symptoms associated with the "Cicada" variant are generally similar to other Omicron subvariants, commonly including a very sore throat, mild fever or chills, runny or blocked nose, dry cough, fatigue, body aches, and sometimes gastrointestinal issues.

Why It Matters

The "Cicada" variant's numerous mutations raise concerns about its potential to evade immune responses from prior infections or existing COVID-19 vaccines. While current evidence does not suggest that BA.3.2 causes more severe illness than previous variants, its ability to bypass immunity could lead to increased transmissibility and a greater number of infections, potentially impacting vulnerable populations. The emergence of such a highly mutated strain underscores the ongoing need for genomic surveillance, vaccination, and public health precautions to track the virus's evolution and mitigate its impact.

Geographic Location

• South Africa (variant first identified in November 2024)
• United States (first detected in a traveler in June 2025, detected in 25-29 states as of February 2026 via wastewater surveillance and clinical samples)
• Netherlands (traveler from this country was the first U.S. identification in June 2025)
• Denmark (30% prevalence of BA.3.2 between November 2025 and January 2026)
• Germany (30% prevalence of BA.3.2 between November 2025 and January 2026)
• Puerto Rico (variant detected)
• Japan (variant detected)
• Kenya (variant detected)
• United Kingdom (variant detected)
• Australia (variant detected)